Open Access

BMC Pulmonary Medicine

Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis



Takumi Yoshikawa[†], Mitsuo Otsuka^{*}, Hirofumi Chiba[†], Kimiyuki Ikeda, Yuki Mori, Yasuaki Umeda, Hirotaka Nishikiori, Koji Kuronuma and Hiroki Takahashi

Correction to: BMC Pulm Med (2020) 20:27 https://doi.org/10.1186/s12890-020-1060-y

Following publication of the original article [1], the authors have flagged that there is an error in Fig. 3.

Namely, asterisks indicating significant difference are missing in the figure.

Please see the correct version of Fig. 3 in this correction article.

The authors apologize for any inconvenience caused.

Published online: 07 May 2020

Reference

 Yoshikawa T, et al. Surfactant protein A as a biomarker of outcomes of antifibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2020;20:27. https://doi.org/10.1186/s12890-020-1060-y.

The original article can be found online at https://doi.org/10.1186/s12890-020-1060-y

* Correspondence: ohtsukam@sapmed.ac.jp

⁺Takumi Yoshikawa and Hirofumi Chiba contributed equally to this work. Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, 1-37, South 1-West 16, Chuo-ku, Sapporo, Hokkaido 060-8543, Japan



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, with http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 3 Relative change in SP-A, SP-D, and KL-6 levels in the initial 3 and 6 months in the stable and progression groups. Changes in SP-A at 3 and 6 months, SP-D at 6 months, and KL-6 at 3 and 6 months were significantly smaller in the stable group than the progression group (*p < 0.05). Data were analyzed by Mann-Whitney U test. Horizontal line indicates median concentration. The upper and lower limits of the box indicate the inter-quartile range